search
Back to results

Pirfenidone and Its Role in Burn Wound Healing

Primary Purpose

Second-degree Burn

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Pirfenidone Oral Product
Sponsored by
Universidad Autonoma de Nuevo Leon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Second-degree Burn focused on measuring Burns, Partial-thickness burn wounds, Re-epithelization, Second-Degree Wound, Pirfenidone, Wound Healing

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with second-degree burns from any etiology with less than 24 hours of evolution.

Exclusion Criteria:

  • Patients <18 years old
  • Patients allergic to pirfenidone
  • Pregnant patients
  • Patients with renal or hepatic failure
  • Patients who are not able to take the medication orally
  • Conditions or drugs that alter wound healing (i.e. any kind of diabetes, lupus, having a history of using steroids, rheumatoid arthritis)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    No Intervention

    Arm Label

    Pirfenidone 600 mg

    Usual Care

    Arm Description

    Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.

    Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.

    Outcomes

    Primary Outcome Measures

    Epidermal re-epithelization
    Thickness of the epidermal re-epithelization measured in micrometers using a digitial image software

    Secondary Outcome Measures

    Presence of Fibrosis
    A qualitative assessment of the presence of fibrotic tissue in the extracellular matrix using a light field microscope.
    Basal Membrane Integrity
    A qualitative assessment of the presence and integrity of the basal membrane using a light field microscope.
    Presence of Collagen Fibers
    A qualitative assessment of the presence of collagen fibers in the dermis using a light field microscope.
    Clinical Evaluations of Wound's Re-Epithelization
    Clinical evaluation of wound's re-epithelization based on the judgement of an experienced plastic surgeon

    Full Information

    First Posted
    May 7, 2018
    Last Updated
    May 17, 2018
    Sponsor
    Universidad Autonoma de Nuevo Leon
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03530150
    Brief Title
    Pirfenidone and Its Role in Burn Wound Healing
    Official Title
    Pirfenidone and Its Efficacy in Wound Re-Epithelization in Patients With Second-Degree Burns: A Proof-of-Concept Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    January 1, 2017 (Actual)
    Primary Completion Date
    June 22, 2017 (Actual)
    Study Completion Date
    June 22, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Universidad Autonoma de Nuevo Leon

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Burn patients which skin has been lost a rapid growth of the skin is a foremost in their treatment. Due to the injury, burn patients undergo a systemic inflammation that helps the skin heal faster. However, several studies have shown that this inflammation increases the levels of several inflammatory molecules that impairs skin growing, which further delays the recovery of burn patients. As such, by inhibiting these inflammatory molecules with the administration of a medication called pirfenidone burn patients might present faster rates of skin growth and recovery. Thus, patients suffering from a burn injury will be recruited at the emergency department of the Hospital University in Monterrey Mexico. Afterward, patients will be randomized to either receive pirfenidone 600 mg orally once per day or usual care consisting of covering the wound with hydrocolloid dressings. To assess the amount of newly growth skin investigators will take a small piece of the skin to further evaluate it through a microscope.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Second-degree Burn
    Keywords
    Burns, Partial-thickness burn wounds, Re-epithelization, Second-Degree Wound, Pirfenidone, Wound Healing

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Model Description
    Burn patients will be divided to receive either 600 mg of pirfenidone or usual care
    Masking
    InvestigatorOutcomes Assessor
    Masking Description
    The principal investigator, the person in charge of gathering the data, and the person analyzing the data will be blinded
    Allocation
    Randomized
    Enrollment
    8 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Pirfenidone 600 mg
    Arm Type
    Active Comparator
    Arm Description
    Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
    Arm Title
    Usual Care
    Arm Type
    No Intervention
    Arm Description
    Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
    Intervention Type
    Drug
    Intervention Name(s)
    Pirfenidone Oral Product
    Other Intervention Name(s)
    Kitoscell
    Intervention Description
    A pill containing 600 mg of pirfenidone
    Primary Outcome Measure Information:
    Title
    Epidermal re-epithelization
    Description
    Thickness of the epidermal re-epithelization measured in micrometers using a digitial image software
    Time Frame
    Day 7
    Secondary Outcome Measure Information:
    Title
    Presence of Fibrosis
    Description
    A qualitative assessment of the presence of fibrotic tissue in the extracellular matrix using a light field microscope.
    Time Frame
    Day 0 and 7
    Title
    Basal Membrane Integrity
    Description
    A qualitative assessment of the presence and integrity of the basal membrane using a light field microscope.
    Time Frame
    Day 0 and 7
    Title
    Presence of Collagen Fibers
    Description
    A qualitative assessment of the presence of collagen fibers in the dermis using a light field microscope.
    Time Frame
    Day 0 and 7
    Title
    Clinical Evaluations of Wound's Re-Epithelization
    Description
    Clinical evaluation of wound's re-epithelization based on the judgement of an experienced plastic surgeon
    Time Frame
    Day 7

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with second-degree burns from any etiology with less than 24 hours of evolution. Exclusion Criteria: Patients <18 years old Patients allergic to pirfenidone Pregnant patients Patients with renal or hepatic failure Patients who are not able to take the medication orally Conditions or drugs that alter wound healing (i.e. any kind of diabetes, lupus, having a history of using steroids, rheumatoid arthritis)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gabriel A Mecott-Rivera, MMS
    Organizational Affiliation
    Universidad Autonoma de Nuevo Leon
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    All information will be delivered by request. Possible individual participant data includes: Database Original Protocol Informed Consent
    IPD Sharing Time Frame
    Data will be available from May 2018 to May 2020

    Learn more about this trial

    Pirfenidone and Its Role in Burn Wound Healing

    We'll reach out to this number within 24 hrs